病毒学
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
免疫系统
2019年冠状病毒病(COVID-19)
2019-20冠状病毒爆发
Sars病毒
倍他科诺病毒
医学
免疫学
生物
传染病(医学专业)
疾病
病理
爆发
作者
Weixu Feng,Zhuo Chen,Lianpeng Wu,Xiuting Chen,Qingfeng Li,Yunru Xiang,Yanru Guo,Wangqi Du,Jun Chen,Shanli Zhu,Haiyan Dong,Xiangyang Xue,Kong‐Nan Zhao,Lifang Zhang
标识
DOI:10.1016/j.intimp.2024.113362
摘要
Here, we report that four functional fragments of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) spike protein including receptor binding motif (RBM), fusion peptide (FP), heptad repeat 1 (HR1) and heptad repeat 2 (HR2) were chosen to develop a recombinant S subunit protein vaccine. This recombinant protein consisting of S230 amino acids (aa) (S230) bound specifically to the antibody from COVID-19-patients serum, which showed very strong antigenicity. The S230 was then engineered to present on the surface of Hepatitis B core (HBc) virus-like particles (VLPs) to develop HBc-S230 chimeric VLPs vaccine. Both vaccines induced strong humoral and cellular immune responses in mice, however, HBc-S230 chimeric VLPs elicited significantly higher immunogenicity than the S230. HBc-S230 chimeric VLPs promoted to generate not only dramatically higher levels of S230-specific serum antibodies, but also marked higher CD4+/CD8 + T cells ratio and substantially higher yields of IFN-γ and IL-6. Furthermore, HBc-S230 chimeric VLPs induced serum antibodies that could effectively neutralize the infection with three SARS-CoV-2 pseudoviruses (Wild type, Delta and Omicron). Our results demonstrated that HBc-S230 chimeric VLPs immunization conveyed the humoral immunity, which lasted longer than six months. Clearly, HBc-S230 chimeric VLPs enhanced immunogenicity of the S230, which could provide potent and durable protection against SARS-CoV-2 infection, indicating that HBc-S230 chimeric VLPs possessed great potential for developing highly immunogenic vaccines against SARS-CoV-2.
科研通智能强力驱动
Strongly Powered by AbleSci AI